MNPR
USDMonopar Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$85.950
Kõrge
$86.140
Madal
$80.105
Maht
0.14M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
510.3M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.07M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125
Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics with a Overweight rating and announces Price Target of $125.
Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142
Raymond James analyst Chris Raymond maintains Monopar Therapeutics with a Strong Buy and raises the price target from $80 to $142.
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics with a Buy and raises the price target from $70 to $105.
Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95
Piper Sandler analyst Biren Amin maintains Monopar Therapeutics with a Overweight and raises the price target from $76 to $95.
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics with a Buy and raises the price target from $60 to $85.
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $104
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics with a Buy and raises the price target from $87 to $104.
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics", "Monopar", or the "Company"), a clinical-stage biopharmaceutical company developing innovative
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.